Author:
Leicher Laura W.,de Graaf Jacques C.,Coers Wilko,Tascilar Metin,de Groot Jan Willem B.
Funder
Nordic Pharma International
Publisher
Springer Science and Business Media LLC
Reference14 articles.
1. Van Cutsem E, Cervantes A, Nordlinger B, Arnold D, ESMO Guidelines Working Group. Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(Suppl 3):iii1–9.
2. National Comprehensive Cancer Network (NCCN) Guidelines. Colon Cancer. v2.2016. Available at: http://www.nccn.org . Accessed 24 Mar 2016.
3. National Comprehensive Cancer Network (NCCN) Guidelines. Rectal Cancer. v1.2016. Available at: http://www.nccn.org . Accessed 24 Mar 2016.
4. Cassidy J, Twelves C, Van Cutsem E, Hoff P, Bajetta E, Boyer M, et al. First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol. 2002;13:566–75.
5. Van Cutsem E, Hoff PM, Harper P, Bukowski RM, Cunningham D, Dufour P, et al. Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials. Br J Cancer. 2004;90:1190–7.
Cited by
29 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献